$2.17
+0.09 (+4.33%)
Open$2.09
Previous Close$2.08
Day High$2.20
Day Low$2.04
52W High$2.61
52W Low$1.09
Volume—
Avg Volume401.2K
Market Cap58.56M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+677.4% upside
Current
$2.17
$2.17
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.0K | 105.2K | 11.20M |
| Net Income | -50,067,872 | -87,804,140 | 1.78M |
| Profit Margin | -91,866.0% | -87,272.7% | 15.9% |
| EBITDA | -51,557,521 | -95,439,682 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -48.7% | -48.7% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |